CIK 0001610618
CDTX Cidara Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 30, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Signals
Open-market buys and sells at Cidara Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Ra Capital Management, L.p. director, owner buy | $100M 2,272,727 shares | +208% | - | |
| 31Weak | Chrysa Mineo director buy | $74k 3,320 shares | - | - | |
| 29Weak | Leslie Tari CHIEF SCIENTIFIC OFFICER sell | $39k 1,773 shares | -10% | - | |
| 39Weak | Shane Ward COO & CLO sell | $37k 1,664 shares | -10% | - |
Transactions
The last 30 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 26, 2025 | Ra Capital Management, L.p. director, owner | POpen-market purchase Common Stockindirect: See footnotes | +2,272,727 | $44.00 | $100M | 3,365,523 | Jun 30, 2025 |
| Jun 18, 2025 | Daniel D Burgess director | AGrant or award Stock Option (right to buy)derivative | +11,100 | $0.00 | $0 | 11,100 | Jun 18, 2025 |
| Jun 18, 2025 | Joshua Resnick director | AGrant or award Stock Option (right to buy)derivative | +5,079 | $0.00 | $0 | 5,079 | Jun 18, 2025 |
| Jun 18, 2025 | Ryan Spencer director | AGrant or award Stock Option (right to buy)derivative | +11,100 | $0.00 | $0 | 11,100 | Jun 18, 2025 |
| Jun 18, 2025 | Theodore R Schroeder director | AGrant or award Stock Option (right to buy)derivative | +11,100 | $0.00 | $0 | 11,100 | Jun 18, 2025 |
| Jun 18, 2025 | Chrysa Mineo director | AGrant or award Stock Option (right to buy)derivative | +11,100 | $0.00 | $0 | 11,100 | Jun 18, 2025 |
| Jun 18, 2025 | James Merson director | AGrant or award Stock Option (right to buy)derivative | +11,100 | $0.00 | $0 | 11,100 | Jun 18, 2025 |
| Jun 18, 2025 | Ra Capital Management, L.p. director | AGrant or award Stock Option (right to buy)derivativeindirect: See Footnotes | +5,079 | $0.00 | $0 | 5,079 | Jun 18, 2025 |
| Jun 18, 2025 | Carin Canale-Theakston director | AGrant or award Stock Option (right to buy)derivative | +11,100 | $0.00 | $0 | 11,100 | Jun 18, 2025 |
| Jun 18, 2025 | Bonnie L Bassler director | AGrant or award Stock Option (right to buy)derivative | +11,100 | $0.00 | $0 | 11,100 | Jun 18, 2025 |
| Jun 2, 2025 | Chrysa Mineo director | POpen-market purchase Common Stock | +2,270 | $21.71 | $49k | 2,270 | Jun 4, 2025 |
| Jun 3, 2025 | Chrysa Mineo director | POpen-market purchase Common Stock | +1,050 | $23.44 | $25k | 3,320 | Jun 4, 2025 |
| May 1, 2025 | Nicole Negar Davarpanah Chief Medical Officer | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 31,692 | May 12, 2025 |
| May 1, 2025 | Nicole Negar Davarpanah Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | May 12, 2025 |
| Mar 31, 2025 | Shane Ward COO & CLO | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 39,674 | Apr 2, 2025 |
| Mar 31, 2025 | Jeffrey Stein President & CEO | AGrant or award Employee Stock Option (right to buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Apr 2, 2025 |
| Mar 31, 2025 | Shane Ward COO & CLO | AGrant or award Employee Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 2, 2025 |
| Mar 11, 2025 | Leslie Tari CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock | -1,773 | $21.96 | $39k | 16,215 | Mar 13, 2025 |
| Mar 11, 2025 | Shane Ward COO & CLO | SOpen-market sale Common Stock | -1,664 | $21.96 | $37k | 14,674 | Mar 13, 2025 |
| Feb 24, 2025 | Frank Karbe Chief Financial Officer | AGrant or award Common Stock | +57,500 | $0.00 | $0 | 57,500 | Feb 26, 2025 |
| Feb 24, 2025 | Frank Karbe Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Feb 26, 2025 |
| Jan 3, 2025 | Ra Capital Management, L.p. director | AGrant or award Stock Option (right to buy)derivativeindirect: See Footnotes | +22,200 | $0.00 | $0 | 22,200 | Jan 7, 2025 |
| Jan 3, 2025 | Joshua Resnick director | AGrant or award Stock Option (right to buy)derivative | +22,200 | $0.00 | $0 | 22,200 | Jan 7, 2025 |
| Dec 17, 2024 | Daniel D Burgess director | AGrant or award Stock Option (right to buy)derivative | +20,500 | $0.00 | $0 | 20,500 | Dec 19, 2024 |
| Dec 17, 2024 | Bonnie L Bassler director | AGrant or award Stock Option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Dec 19, 2024 |
| Dec 17, 2024 | Carin Canale-Theakston director | AGrant or award Stock Option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Dec 19, 2024 |
| Dec 17, 2024 | Chrysa Mineo director | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Dec 19, 2024 |
| Dec 17, 2024 | Theodore R Schroeder director | AGrant or award Stock Option (right to buy)derivative | +20,500 | $0.00 | $0 | 20,500 | Dec 19, 2024 |
| Nov 26, 2024 | Ra Capital Management, L.p. director | AGrant or award Common Stockindirect: See footnotes | +389,716 | $14.91 | $5.8M | 1,092,796 | Nov 29, 2024 |
| Nov 26, 2024 | Ra Capital Management, L.p. director | AGrant or award Pre-Funded Warrants (Right to Buy)derivativeindirect: See footnotes | +1,286,786 | $14.91 | $19M | 1,286,786 | Nov 29, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Daniel D Burgessdirector
- Bonnie L Basslerdirector
- Carin Canale-Theakstondirector
- Nicole Negar DavarpanahChief Medical Officer
- Frank KarbeChief Financial Officer
- James Mersondirector
- Chrysa Mineodirector
- Ra Capital Management, L.p.owner, director
- Joshua Resnickdirector
- Theodore R Schroederdirector
- Ryan Spencerceo, officer, director
- Jeffrey SteinPresident & CEO
- Leslie TariCHIEF SCIENTIFIC OFFICER
- Shane WardCOO & CLO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.